Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
121 results about "Double mutant" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibodies immunoreactive with mutant 5-enolpyruvlshikimate-3-phosphate synthase
Antibodies immunoreactive to double mutant EPSPS are provided, and in an embodiment the double mutant EPSPS is one in which the wild-type EPSPS is substituted at residue 102 with isoleucine and at residue 106 with serine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.
Owner:M S TECH
Tool for efficient site-specific transposition of genes and application of tool
ActiveCN105646719ARealize transposition functionRealize site-specific transgeneHydrolasesAntibody mimetics/scaffoldsGene engineeringAnimal genome
The invention relates to the field of gene engineering and particularly discloses a tool for efficient site-specific transposition of genes. The tool comprises or can produce a gRNA-Cas9 protein (without incision enzyme activity)-PB transposase compound, and gRNA targets the specific site of a genome; the Cas9 protein without incision enzyme activity is double-mutant Cas9 protein with 10th-site amino acid residue D mutating into A and 840th-site amino acid residue H mutating into A. Through design of gRNA (guide RNA) targeting the animal genome, under the coexpression condition of gRNA and site-specific transposase, PB transposase is targeted to a specific position of the genome along with a CRISPR / cas9 and gRNA compound, the PB transposase realizes a transposition function at the specific site, accordingly, donor plasmids (carriers containing exogenous target genes) are simultaneously co-transfected, the exogenous target carriers can be transposed to the specific site in the genome through transposition, and site-specific transposition of the genes is realized.
Owner:WUXI MATERNAL & CHILD HEALTH HOSPITAL
Immunogenic compositions comprising DAL/DAT double mutant, auxotrophic attenuated strains of listeria and their mehods of use
InactiveUS20050048081A1Bacterial antigen ingredientsViral antigen ingredientsMicrobiologyGenus Listeria
The invention includes auxotrophic attenuated mutants of Listeria and methods of their use as vaccines.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
RecA mutants
InactiveUS7176007B2Improve concentrationEliminate requirementsSugar derivativesMicrobiological testing/measurementMutated proteinDouble mutation
The present invention provides RecA mutant proteins, having either a single mutation or a double mutation. The RecA mutant proteins are highly proficient in both SSB displacement and steady state binding of DNA in the presence or absence of SSB as compared to the wild-type protein. The single RecA mutant, RecAΔC17, has 17 amino acid residues removed from the carboxyl terminus. The double mutant RecA, RecAΔC17 / E38K, combines the 17 amino acid residue C-terminal deletion of RecAΔC17, with a single amino acid change from Glutamate to Lysine at position 38. These RecA mutant proteins are pH sensitive allowing control over formation of products. Hence, methods of using the novel RecA mutants and kits having the RecA mutants as components thereof are also contemplated by the present invention.
Owner:WISCONSIN ALUMNI RES FOUND
Yeast arrays, methods of making such arrays, and methods of analyzing such arrays
This patent describes a novel method of detecting genetic interactions in yeast. This method can also be used to screen for function of biological effectors on yeast. The method encompasses crossing yeast strains with genetic alterations to acquire double mutants. The phenotypes of these double mutants are then checked to detect genetic interactions between the double mutants. This method can be used to assign function to yeast genes and their viral, prokaryotic, and eukaryotic homologs, and aptamers. It can also be used to study yeast two hybrid interactions and to find genes that regulate certain yeast promoters.
Owner:BOONE CHARLES
Non-nucleoside reverse transcriptase inhibitors
Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pyrimidine compound, EGFR inhibitor and application of EGFR inhibitor
InactiveCN106083736AInhibitory activitySuppression of resistance mutationsOrganic active ingredientsNervous disorderDiseaseSide effect
The invention discloses a pyrimidine compound, an EGFR inhibitor and application of the EGFR inhibitor. The pyrimidine compound is prepared from a compound shown in the formula I or pharmaceutically acceptable salt thereof, a stereoisomer, and a solvate or prodrug. The EGFR inhibitor contains the pyrimidine compound. The pyrimidine compound can inhibit activated or resistant mutation of one or more kinds of EGFRs, can inhibit proliferation of the EGFR T790M / L858R double-mutant enzyme in the nanomolar concentration, but has a weak inhibiting effect on the wild EGFR enzyme; the pyrimidine compound is applicable to treatment of the EGFR-sensitive mutations cancer and also suitable for cases with secondary dug resistance in present EGFR-TKI treatment; meanwhile, toxic and side effects caused by inhibition on the wild EGFR are greatly reduced due to the mutation selectivity of the pyrimidine compound, and the pyrimidine compound is an ideal treatment drug for diseases caused by EGFR mutation.
Owner:TETRANOV PHARMA CO LTD
β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
ActiveUS7186700B2Preventing and suppressing emergenceBiocidePeptide/protein ingredientsMedicineLamivudine resistance
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and / or suppressing the emergence of the HBV double mutant (L528M / M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.
Owner:NOVARTIS AG
Methods of inducing immune responses through the administration of auxtrophic attenuated dal/dat double mutant Listeria strains
The present invention includes a method of eliciting a T-cell immune response to an antigen in mammal. The method of eliciting a T-cell immune response includes administering mammal an auxotrophic attenuated strain of listeria which expresses the antigen. The auxotrophic attenuated strain of listeria includes a mutation in at least one gene whose protein product is essential for growth of bacteria.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
68th and 109th double mutant enzyme of D-psicose 3-epimerase and application thereof
InactiveCN103849612AHigh catalytic activityFunction increaseMicroorganism based processesOxidoreductasesGenes mutationGenetics
The invention provides a 68th and 109th double mutant enzyme of D-psicose 3-epimerase and an application thereof, and belongs to the technical field of enzyme genetic engineering. The invention discloses the mutant enzyme Y68I / G109P which is obtained by using the D-psicose 3-epimerase (called DPE enzyme for short) derived from clostridium bolteae ATCCBAA-613 as a parent and utilizing a gene mutation technology for respectively replacing 68th tyrosine Tyr and 109th glycine Gly with isoleucine Ile and praline Pro. The heat stability and catalytic activity of the mutant enzyme Y68I / G109P are improved, therefore, the mutant enzyme Y68I / G109P has important industrial application value.
Owner:JIANGNAN UNIV
KASP marker primers for detecting SNP mutations in rice ALS genes and application thereof
InactiveCN107653337ARapid identificationImprove throughputMicrobiological testing/measurementDNA/RNA fragmentationAgricultural scienceAcetolactate Synthetase
The invention discloses KASP marker primers for detecting simultaneous SNP mutations in Ser627Asn and Val643Met of rice ALS genes. In terms of the simultaneously generated SNP mutations in the Ser627Asn and the Val643Met of the rice ALS genes, when the phenotype of the double mutant ALS genes is labeled, the sequence of the double mutant ALS genes is a new unreported gene sequence which can primarily determine the labeled material, and then accurately determine the labeled rice material throughdouble KASP markers in the genes so as to carry out quick, highly accurate and high-throughput identification of anti-acetyl lactate synthase inhibitor herbicides of the rice. When the KASP marker primers are used for molecular marker-assisted breeding of hybrid rice varieties with herbicide resistance, the results of two pairs of KASP markers are validated mutually in order to effectively remove sterile line seedlings obtained via 'Tako' selfing by spraying herbicides.
Owner:HUNAN HYBRID RICE RES CENT
Detoxified recombinant botulinum neurotoxin
ActiveUS8586081B2Development is reduced and preventedSymptom is reduced and preventedBacterial antigen ingredientsPeptide/protein ingredientsEscherichia coliAntidote
Owner:SINGH BAL RAM
Recombinant soluble human FGFR2 extracellular fragment and production method and application thereof
The present invention discloses a recombinant soluble FGFR2 extracellular domain and the production method as well s the application of the extracellular domain. The present invention is based on the high-efficient expression FGFR2 of escherichia coli. Qualitative and quantitative researches have done concerning a plurality of factors that affect the renaturing efficiency. A proper method for recombinant soluble FGFR2 extracellular domain is determined. The renaturing efficiency can be of 10 percent to 20 percent. The present invention is of low cost and short cycle. The present invention is suitable for mass production. And the present invention takes advantage of the combination of dissociative extracellular domain of FGFRs with the FGFs in the tumor tissue to reduce the amount of dissociative FGFs, competitively leading to the repressive FGFs signals and the restraining proliferation and transfer of tumor as well as the depressed formation of blood vessels. S252W+P253R extracellular domain and double-mutant FGFR2 extracellular domain are of the best efficiency.
Owner:JINAN UNIVERSITY
Retinal dystrophin transgene and methods of use thereof
InactiveUS20080044393A1Alleviation of muscular dystrophy symptomReduce the possibilityBiocideNervous disorderBehavioral studyTransgene
Duchenne muscular dystrophy (DMD) is a progressive muscle disease that is caused by severe defects in the dystrophin gene and results in the patient's death by the third decade. The present invention utilizes the Double Mutant mice (DM) as an appropriate human model for DMD as these mice are deficient for both dystrophin and utrophin (mdx / +, utrn − / −), die at 3 months of age and suffer from severe muscle weakness, pronounced growth retardation, kyphosis, weight loss, slack posture, and immobility. Expression from a transgene of novel human retinal dystrophin Dp260 was shown to prevent premature death and reduce the severe muscular dystrophy phenotype to a mild clinical myopathy. Electromyography, histology, radiography, magnetic resonance imaging, and behavior studies concluded that DM transgenic mice grew normally, had normal spinal curvature and mobility, and had reduced muscle pathology. EMG and histologic data from transgenic DM mice showed decreased abnormalities to levels typical of mild myopathy, while the DM mice exhibited severe abnormalities commonly seen in human dystrophinopathies. The transgenic DM mice also had measurable movement levels comparable to those of untreated mdx mice and controls.
Owner:WHITE ROBERT L +2
High-thermal-stability mutant of D-allulose-3-epimerase and application thereof
ActiveCN106350498AExtend the life cycleImprove thermal stabilityIsomerasesFermentationHalf-lifeWild type
The invention discloses a high-thermal-stability mutant of D-allulose-3-epimerase and an application of the high-thermal-stability mutant of D-allulose-3-epimerase. The 116th bits of serine of the mutant at D-allulose-3-epimerase is mutated to isoleucine, and the 251st bits of lysine is mutated to leucine, and a double mutant enzyme S116I / K251L is obtained. According to the invention, the 116th bit of serine (Ser, S) of D-allulose-3-epimerase BsDPE of Burkholderia sp. MR1 is mutated to isoleucine (Ile, I), and the 251st bits of lysine (Lys, K) is mutated to leucine (Leu, L), thus the thermal stability of the double mutant enzyme S116I / K251L obtained therefrom is significantly improved; and the half-life period at 60 DEG C is improved from the wild type 337.3 min to 417.9 min at present, and is 1.24 times o the wild type; the using cycle of the enzyme in compounding D-allulose is largely prolonged; the high-thermal-stability mutant of D-allulose-3-epimerase has important industrial application value.
Owner:LIVINGZONE SHANGHAI BIO CHEM TECH CO LTD
Mutant of cyclodextrin glucosyl transferase having highly alpha-cyclodextrin yielding property and mutation method
InactiveCN101503681AEase of industrial productionStrong specificityTransferasesMicroorganism based processesWild typeGene engineering
The invention relates to a mutant of a cyclodextrin glucosyltransferase with the capability of highly yielding alpha-cyclodextrin and a mutation method, which belong to the fields of gene engineering and enzyme engineering. The invention improves the specificity of products of the cyclodextrin glucosyltransferase (CGT enzyme for short), provides a mutant proposal for improving the capability of CGT enzyme from Peanibacillus macerans JFB05-01 (CCTCC NO: M 208063) for producing the alpha-cyclodextrin, and substitutes Asp on the 372 position of the CGT enzyme for Lys, and Tyr on the 89 position as Asp and Arg to respectively obtain single mutant enzyme D372K, Y89D and Y89R; the alpha-cyclodextrin production capacity of the obtained mutant enzyme is improved compared with wild type CGT enzymes; genetic fragments of the CGT enzyme with Lys 372 are substituted by corresponding genetic fragments of Y89R so as to obtain double mutant enzyme D372K / Y89R; and the yield of the alpha-cyclodextrin of the ouble mutant enzyme D372K / Y89R is improved by 1.5 times compared with the wild type CGT enzyme, while the yield of the beta-cyclodextrin is reduced by 57 percent. The mutants are more favorable for industrial production of the beta-cyclodextrin than the wild type CGT enzymes.
Owner:JIANGNAN UNIV
Target-specificity dual-mutant amalgamation protein
ActiveCN101343328ANo lethal effectLow costPolypeptide with localisation/targeting motifPeptide/protein ingredientsPseudomonas aeruginosa exotoxin ACytotoxicity
The invention discloses target specific double mutant fusion protein, which is established by human gonadotropin releasing hormone mutant (mGnRH) and recombinant pseudomonas aeruginosa exotoxin A mutant (PE38m4a) fusion protein. The mGnRH-PE38m4a protein provided by the invention has obvious specific binding activity and cytotoxicity to the tumor cell lines which comprise colon cancer HT-29 cells, oophoroma OVCAR3 cells, cervical adenocarcinoma HeLa cells or liver cancer HepG-2 cells, and the like; the normal cells basically have no lethal function; the activity of the fusion protein is enhanced by approximate nine to ten times compared with the activity of natural PEA; the cost is low, the method is simple, therefore the target specific double mutant fusion protein is more suitable for industrialized production.
Owner:SHANGHAI SILINGE BIOTECHNOLOGY CO LTD
Use of an avirulent bordetella mutant as a live vaccine vector
The present invention pertains to Bordetella bacteria having a double mutation, a first mutation in a gene of the Type III secretion system and a second mutation in a gene of the adenylate cyclase toxin (CyaA) locus of the bacteria so that the mutations result in no Type III secretion system, a non-functional Type III secretion system, no CyaA protein, or a non-functional CyaA protein or a combination thereof. The Bordetella bacteria double mutant is attenuated while maintaining the efficacy of the bacteria to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and immunizing a mammal against a disease caused by infection of Bordetella bacteria or a disease caused by a pathogen.
Owner:PENN STATE RES FOUND
Genetically engineered g-alpha proteins and uses thereof
ActiveUS20110212476A1Efficient processCompound screeningApoptosis detectionDiseaseGPCR signaling pathway
The present invention relates to novel engineered Ga proteins and assay methods of using such proteins to advance drug discovery. Engineered Ga proteins described by the invention contain alterations of at least one and preferably two or more amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A preferred engineered protein disclosed here is a double mutant, Gαπ R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function both in terms of GTPase activity (GTP hydrolysis) and GDP dissociation. This synergistic effect may have a profound influence on the way GPCR signaling pathways are examined for the development of new pharmacotherapies, particularly in the field of central nervous system disorders such as Parkinson's disease.
Owner:BELLBROOK LABS
Herpes virus complementing cell line
InactiveUS6841373B2Reduce the possibilityAvoid reorganizationBiocideGenetic material ingredientsICP8Herpes simplex virus DNA
The present invention is directed to a cell line capable of supporting replication of a growth-defective Herpes Simplex Virus strain; specifically a replication-defective HSV-2 double mutant. Particularly disclosed is a cell line that expresses the ICP8 protein and the UL5 protein of Herpes Simplex Virus. This cell line is useful to propagate a replication-defective HSV-2 vaccine strain that contains mutations and / or deletions in the ICP8 and UL5 genes.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and preparation method thereof
ActiveCN102994468AIncreased substrate specificityIncrease productionBacteriaMicroorganism based processesArginineWild type
The invention discloses cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and a preparation method thereof, and belongs to the field of genetic engineering and enzyme engineering. 195-bit tyrosine (Tyr) of CGTase of P.macerans strain JFB05-01 (CCTCC NO:M208063) is replaced by serine (Ser), 260-bit tyrosine (Tyr) is replaced by arginine (Arg), and 265-bit glutamine (Gln) is replaced by lysine (Lys), so that the AA-2G yield is respectively improved by 23 percent, 44 percent and 40 percent. According to combined mutation of the mutant strains, double mutants Y195S / Y260R, Y195S / Q265K and Y260R / Q265K and A three-point mutant Y195S / Y260R / Q265K are obtained. A Glycosyl donor is produced by the maltodextrin, so that the AA-2G yield is respectively improved by 57 percent, 49 percent, 55 percent and 59 percent; and compared with the mild type CGTase, the mutant strains facilitate the production of the AA-2G for glycosyl donors by using maltodextrin.
Owner:JIANGNAN UNIV
Genetically engineered bacterium for expressing heat resistant type dextransucrase, as well as construction method and application of genetically engineered bacterium
InactiveCN107201332AIncrease enzyme activitySave production capitalBacteriaTransferasesBiotechnologyEngineered genetic
The invention discloses a genetically engineered bacterium for expressing heat resistant type dextransucrase, as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium for expressing the heat resistant type dextransucrase is constructed as follows: a dex-YG gene obtained by cloning is inserted into an expression vector pET28(+)a, so as to obtain a recombinant expression plasmid pET28(+) / dex-YG which is taken as a template; site-directed mutagenesis is performed on a 473-site and a 856-site, heat-resistant double-mutants P473S / P856S with high enzyme activity is obtained after screening, and a recombinant engineered bacterium dex-YG-thMu01 is obtained from the conversion of a host bacterium E.ColiBL21(DE3). The genetically engineered bacterium dex-YG-thMu01 disclosed by the invention have the characteristics of heat resistance and high enzyme activity, and provide a certain basis for application of the genetically engineered bacterium dex-YG-thMu01 to industrial production of the dextransucrase; the productive capital can be saved.
Owner:HEFEI UNIV OF TECH
2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application
ActiveCN107245075ANovel structureEasy to synthesizeOrganic active ingredientsOrganic chemistrySynthesis methodsT790M
The invention provides 2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application and belongs to the technical field of anti-cancer drugs. The compounds are novel in structure and easy in synthesis, have inhibiting activity to epidermal growth factor receptor (EGFR) tyrosine kinase, have obvious inhibiting activity to EGFR of a single mutant (L858R) and double mutants (L858R / T790M), have obvious in-vivo and in-vitro anti-tumor activity and can be applied to the treatment of EGFR mutation related cancers, the synthesis raw materials are readily available, and the synthesis method is easy to achieve.
![2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b54d3de-5d0b-4191-8119-8e704efb0283/BDA0001370603960000011.png "2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application")
![2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b54d3de-5d0b-4191-8119-8e704efb0283/BDA0001370603960000031.png "2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application")
![2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b54d3de-5d0b-4191-8119-8e704efb0283/BDA0001370603960000041.png "2,4,6-trisubstituted pyridino[3, 4-d]pyrimidine compounds, salts thereof and application")
Owner:XI AN JIAOTONG UNIV
Non-toxic double mutant forms of pertussis toxin as adjuvants
InactiveUS7169399B2Good immunogenic activityExcellent adjuvantAntibacterial agentsBiocideAntigenGlycine
The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against B. pertussis infection. The invention also relates to the use of a non-toxic double mutant form of pertussis toxin for the manufacture of an adjuvant composition for stimulating or enhancing a protective immune response of an antigen co-administered therewith. The non-toxic double mutant is preferably one in which the glutamic acid 129 amino acid in the S1 sub-unit has been substituted by glycine and the arginine 9 amino acid has been substituted by lysine.
Owner:UCB PHARMA LTD SLOUGH
EGFR (epidermal growth factor receptor) inhibitor for targeted therapy of cancers, and preparation method and application thereof
ActiveCN105585557ANovel chemical structureLittle side effectsOrganic active ingredientsOrganic chemistryChemical structureSide effect
The invention discloses an EGFR (epidermal growth factor receptor) inhibitor for targeted therapy of cancers, and a preparation method and application thereof. The structural formula of the EGFR inhibitor is disclosed as Formula I, wherein R is H, OH, NR', C1-C3 alkyl, C1-C3 alkenyl, aryl or heterocycle, and R' is C1-C3 alkyl. The EGFR inhibitor can be used for preventing and / or treating cancers, such as human skin squamous carcinoma or lung cancer. Compared with the existing inhibitors (such as AZD9291, afatinib and the like), the EGFR inhibitor disclosed by the invention has novel chemical structure. The EGFR inhibitor can selectively inhibit cell lines of EGFR double mutants (EGFRT790M / L858R), and has lower inhibition activities for EGFR wild type cells. Therefore, the EGFR inhibitor disclosed by the invention can be used for treating the patient with lung cancer with EGFRT790M / L858R mutants, and has lower side effect (caused by the inhibition of the wild type EGFR, such as afatinib).
Owner:TSINGHUA UNIV
Cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and preparation method thereof
InactiveCN103122341AIncreased substrate specificityIncrease productionBacteriaTransferasesCyclodextrinWild type
The invention discloses a cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and a preparation method thereof and belongs to the fields of genetic engineering and enzyme engineering. According to the invention, for CGTase derived from peanibacillus macerans, lysine at a 47th site, tyrosine at a 89th site, asparaginate at a 94th site and aspartic acid at a 196th site are respectively mutated into leucine K47L, phenylalanine Y89F, praline N94P and tyrosine D196Y, so that AA-2G yields are respectively increased by 30.7%, 10.9%, 10.0% and 31.7%. Complex mutation is carried out on the mutant strains to obtain double mutants namely K47L / Y89F, K47L / N94P, K47L / D196Y, Y89F / N94P, Y89F / D196Y and N94P / D196Y, three-point mutants namely K47L / Y89F / N94P, K47L / Y89F / D196Y, K47L / N94P / D196Y and Y89F / N94P / D196Y and a four-point mutant namely K47L / Y89F / N94P / D196Y. Yields of AA-2G produced by the mutants while maltodextrin is utilized as a glycosyl donor are respectively increased by 42.6%, 11.0%, 37.6%, 43.6%, 43.6%, 41.6%, 44.5%, 50.5%, 20.8%, 35.6% and 64.4%. Compared with the wild type CGTase, the mutants is more beneficial to production of the AA-2G while the maltodextrin is utilized as the glycosyl donor.
Owner:JIANGNAN UNIV
Rennin mutant with improved enzyme activity and thermal stability
ActiveCN106754840AClear processDouble mutation works wellFungiMicroorganism based processesHeterologousPichia pastoris
The invention discloses a rennin mutant with improved enzyme activity and thermal stability, and belongs to the technical field of enzyme engineering. Glutamine replaces leucine at the 75th position of rennin, threonine replaces methionine at the 222nd position, the amino acids at the positions are subjected to amphimutation to construct the rennin mutant, the mutant is subjected to heterologous expression in pichia pastoris GS115, and expressed crude enzyme is subjected to rennin activation, protease activation and heat resistance detection. The rennin activity of the crude enzyme of double mutants Leu75Gln-Met222Thr reaches 28.0 SU / mL, the C / P value reaches 11.7, the rennin activity and the C / P value are higher than the rennin activity and the C / P value of an original strain P-cMCE by 155.6% and 195.0%. The thermal stability of the rennin mutant after the rennin mutant is maintained at the constant temperature of 45 DEG C for half an hour is reduced by 13.6%.
Owner:JIANGNAN UNIV
Seed plants characterized by delayed seed dispersal
InactiveUS6288305B1Climate change adaptationOther foreign material introduction processesNucleotideGene product
Owner:RGT UNIV OF CALIFORNIA
Seed plants characterized by delayed seed dispersal
The present invention provides a non-naturally occurring seed plant that is characterized by delayed seed dispersal due to ectopic expression of a nucleic acid molecule encoding an AGL8-like gene product. Further provided herein is a non-naturally occurring seed plant, such as an agl1 agl5 double mutant, that is characterized by delayed seed dispersal due to suppression of AGL1 and AGL5 expression in the seed plant. The invention also provides a substantially purified dehiscence zone-selective regulatory element, which includes a nucleotide sequence that confers selective expression upon an operatively linked nucleic acid molecule in the valve margin or dehiscence zone of a seed plant. Also provided by the invention are kits for producing a transgenic seed plant characterized by delayed seed dispersal, such kits containing a dehiscence zone-selective regulatory element.
Owner:RGT UNIV OF CALIFORNIA
Methods for using double-mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
ActiveUS20050069907A1Minimizes stepMicrobiological testing/measurementFermentationPolymerase LBiology
A method and kit for synthesizing a nucleic acid molecule comprising at least one non-canonical nucleoside triphosphate using a double-mutant polymerase having a reduced discrimination between canonical and non-canonical substrates is disclosed. The method comprises incubating a template nucleic acid in a reaction mixture comprising the mutant nucleic acid polymerase and the appropriate canonical and non-canonical nucleoside triphosphates which are desired substrates for the mutant nucleic acid polymerase. The present invention is also a method of determining the sequence of a nucleic acid molecule using the mutant polymerase to create a nucleic acid molecule comprising at least one non-canonical nucleoside triphosphate.
Owner:UNIV OF TEXAS
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com